MX9707944A - Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them. - Google Patents

Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them.

Info

Publication number
MX9707944A
MX9707944A MX9707944A MX9707944A MX9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A
Authority
MX
Mexico
Prior art keywords
methods
compositions
immunogenic
making
oligosaccharide
Prior art date
Application number
MX9707944A
Other languages
Spanish (es)
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Publication of MX9707944A publication Critical patent/MX9707944A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response. This invention also provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.
MX9707944A 1995-06-07 1997-10-15 Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them. MX9707944A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions

Publications (1)

Publication Number Publication Date
MX9707944A true MX9707944A (en) 1998-06-30

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707944A MX9707944A (en) 1995-06-07 1997-10-15 Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them.

Country Status (10)

Country Link
EP (1) EP0831894A1 (en)
JP (1) JPH11506110A (en)
KR (1) KR19990007777A (en)
AU (1) AU725279B2 (en)
CZ (1) CZ327897A3 (en)
IL (1) IL121585A0 (en)
MX (1) MX9707944A (en)
NO (1) NO974727L (en)
NZ (1) NZ309713A (en)
WO (1) WO1996040225A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69708318T3 (en) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville NEISSERIA MENINGITIDIS SEROGRUPPE B GLYCOCONJUGATES AND METHOD FOR THEIR USE
BR9811475A (en) * 1997-07-17 2000-08-15 North American Vaccine Inc Immunogenic conjugates comprising a group b meningococcal porin and an h polysaccharide. influenzae
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
IL153558A0 (en) * 2000-06-20 2003-07-06 Shire Biochem Inc Streptococcus antigens
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
AU2015208821B2 (en) * 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
CA2961694C (en) * 2014-09-26 2022-11-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Vaccines against streptococcus pneumoniae serotype 8
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3074714A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
EP3893926A1 (en) * 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113607939A (en) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 Method for measuring adsorption rate of various combined stock solutions of pneumococcal polysaccharide combined vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (en) * 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE137981T1 (en) * 1990-12-18 1996-06-15 Univ Washington DIALYSAT PRODUCTION SYSTEM WITH PILLS
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae

Also Published As

Publication number Publication date
EP0831894A1 (en) 1998-04-01
WO1996040225A1 (en) 1996-12-19
AU725279B2 (en) 2000-10-12
NO974727L (en) 1997-12-08
KR19990007777A (en) 1999-01-25
NO974727D0 (en) 1997-10-13
CZ327897A3 (en) 1998-02-18
AU5994496A (en) 1996-12-30
NZ309713A (en) 1999-11-29
JPH11506110A (en) 1999-06-02
IL121585A0 (en) 1998-02-08

Similar Documents

Publication Publication Date Title
MX9707944A (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them.
AU8483391A (en) Improved oligosaccharide conjugate vaccines
GR3035081T3 (en) Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
GB9713156D0 (en) Vaccines
WO2000056360A3 (en) Vaccine against antigens from bacteriae
ES8707861A1 (en) Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers.
WO1999055730A3 (en) Polyepitope carrier protein
WO1989006974A3 (en) T-cell epitope as carriers molecule for conjugate vaccines
HK1041825A1 (en) A polysaccharide-protein conjugate or oligosaccharide-protein conjugate, a method for producing the same, and its uses thereof
EP0866133A3 (en) A group b streptococcus vaccine
HUT50048A (en) Process for producing streptococcus protein antigen and pharmaceutical compositions comprising same
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
WO1999052548A3 (en) Conjugate vaccines for the prevention of dental caries
CA2139217A1 (en) Vaccine composition for eliciting an immune response against n-glycolylated gangliosides and its use for cancer treatment
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
AU3991899A (en) Verotoxin b subunit for immunization
DE69535059D1 (en) Borrelia burgdorferi bacterin
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Michon et al. Combination conjugate vaccines against multiple serotypes of group B streptococci
EP0357585A3 (en) Preparation active against infections by pseudomonas aeruginosa, and preparation containing immunoglobulin-gross active against pseudomonas aeruginosa
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
NZ337730A (en) use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees